الفهرس 
Aim of the work`Only 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Psoriasis is a chronic disease, mediated by the human immune system, with cutaneous and systemic manifestations, substantial negative effects on the quality of life and higher prevalence of depression and anxiety. The physical and psychological impacts of psoriasis affect all areas of patient’s functioning. Both anxiety and depression may increase the clinical severity of psoriasis.
Thus, it is not surprising that several studies suggested a role for neurotransmitter, serotonin (5-HT), in the pathogenesis of psoriasis. Additionally, 5-HT is also a main factor in depression, which is one of the main comorbidities of psoriasis.
Furthermore, it has been reported that selective serotonin reuptake inhibitors (SSRIs) influence the topical symptoms of psoriasis. All these results reveal an association between psoriasis–inflammation–serotonin and the serotonergic system may be regulating the process of inflammation observed in psoriasis.
It may affect women and men equally. The estimated prevalence of psoriasis varies widely across different studies.
Aim of the study:
This prospective, analytic, cohort study was conducted at neuropsychiatry department, as faculty of medicine Menoufia University to assess some psychiatric co-morbidities due to psoriasis namely depression and anxiety, the impact of psoriasis on quality of life of psoriatic patients and to investigate whether psoriasis is affected by the use of the serotonin reuptake inhibitor (SSRI), escitalopram.
Patients and methods:
This study included 64 psoriatic patients accounted from Outpatient Clinic of Dermatology, Andrology and Venereology Department, Faculty of Medicine-Menoufia University Hospitals after approval from the Research and Ethics Committee. Only outpatients took part in the study and divided into 2 groups; case group comparing to another control group. Both sexes were included with age ≥18 years.